Table 2.
|
|
Unadjusted |
Model 1 |
Model 2 |
|||
---|---|---|---|---|---|---|---|
N* | Tobit ratio (95% CI) | P | Tobit ratio (95% CI) | P | Tobit ratio (95% CI) | P | |
eGFRcys* (ml/min/1.73 m
2
) |
|
|
|
|
|
|
|
≥ 60 |
757 |
Reference |
- |
Reference |
|
Reference |
- |
45-59 |
684 |
2.11 (1.86-2.41) |
< 0.001 |
1.51 (1.35-1.69) |
< 0.001 |
1.50 (1.34-1.67) |
< 0.001 |
30-44 |
705 |
3.02 (2.66-3.44) |
< 0.001 |
1.97 (1.74-2.22) |
< 0.001 |
1.96 (1.74-2.21) |
< 0.001 |
< 30 |
311 |
5.27 (4.47-6.21) |
< 0.001 |
2.90 (2.47-3.41) |
< 0.001 |
2.83 (2.41-3.33) |
< 0.001 |
ACR (μg/mg) † |
|
|
|
|
|
|
|
< 30 |
1115 |
Reference |
- |
Reference |
|
Reference |
- |
30-299 |
582 |
1.58 (1.39-1.80) |
< 0.001 |
1.08 (0.98-1.20) |
0.130 |
1.06 (0.96-1.19) |
0.214 |
300-999 |
338 |
1.94 (1.66-2.28) |
< 0.001 |
1.09 (0.96-1.25) |
0.191 |
1.08 (0.95-1.23) |
0.238 |
≥ 1000 |
325 |
3.61 (3.08-4.23) |
< 0.001 |
1.56 (1.35-1.81) |
< 0.001 |
1.53 (1.32-1.77) |
< 0.001 |
Phosphate (mg/dL) |
|
|
|
|
|
|
|
< 3 |
265 |
Reference |
- |
Reference |
|
Reference |
- |
3-3.9 |
1427 |
1.08 (0.90-1.28) |
0.419 |
1.02 (0.90-1.17) |
0.739 |
1.02 (0.90-1.17) |
0.711 |
4-4.9 |
646 |
1.59 (1.31-1.93) |
< 0.001 |
1.06 (0.91-1.23) |
0.445 |
1.06 (0.92-1.24) |
0.412 |
≥ 5 |
81 |
3.51 (2.52-4.90) |
< 0.001 |
1.35 (1.04-1.76) |
0.023 |
1.39 (1.08-1.81) |
0.012 |
FGF-23 ‡ |
|
|
|
|
|
|
|
Quartile I |
606 |
Reference |
|
Reference |
|
Reference |
|
Quartile II |
606 |
1.45 (1.25-1.68) |
< 0.001 |
1.07 (0.96-1.20) |
0.230 |
1.08 (0.96-1.21) |
0.206 |
Quartile III |
606 |
2.11 (1.82-2.45) |
< 0.001 |
1.20 (1.06-1.35) |
0.004 |
1.17 (1.04-1.33) |
0.011 |
Quartile IV | 606 | 2.62 (2.26-3.04) | < 0.001 | 1.22 (1.06-1.40) | 0.004 | 1.17 (1.02-1.34) | 0.021 |
*N’s are # observations among participants with TnT measurements, with 7 observation excluded.
Model 1 adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin (per SD), eGFR_CysC, ACR, and phosphate and FGF-23. Model 2 adjusted for: Model 1 + LV mass, ejection fraction.
eGFRcys=cystatin-based estimated glomerular filtration rate. † albumin to creatinine ratio. ‡ fibroblast growth factor 23.